These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 2651991)

  • 21. Cyclosporine potentiates the immunosuppressive effects of anti-interleukin 2 receptor monoclonal antibody therapy.
    Kupiec-Weglinski JW; Hahn HJ; Kirkman RL; Volk HD; Mouzaki A; DiStefano R; Tellides G; Dallman M; Morris PJ; Strom TB
    Transplant Proc; 1988 Apr; 20(2 Suppl 2):207-16. PubMed ID: 3129841
    [No Abstract]   [Full Text] [Related]  

  • 22. Failure of whole blood cyclosporine levels to provide a reliable measure of immunosuppression in clinical heart and heart/lung transplantation.
    White D; Rose M; Wright L; Wallwork J; English TA; Hakim M; Hutter J
    Transplant Proc; 1988 Apr; 20(2 Suppl 2):422-5. PubMed ID: 3129845
    [No Abstract]   [Full Text] [Related]  

  • 23. Pharmacology of cyclosporine (sandimmune). IV. Pharmacological properties in vivo.
    Borel JF
    Pharmacol Rev; 1990 Sep; 41(3):259-371. PubMed ID: 2185490
    [No Abstract]   [Full Text] [Related]  

  • 24. Cyclosporine-associated nephropathy in patients with heart and bone marrow transplants.
    Nizze H; Mihatsch MJ; Zollinger HU; Brocheriou C; Gokel JM; Henry K; Sloane JP; Stovin PG
    Clin Nephrol; 1988 Nov; 30(5):248-60. PubMed ID: 3063420
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantitative analysis of immunosuppression in cyclosporine-treated heart transplant patients with lymphoma.
    Brumbaugh J; Baldwin JC; Stinson EB; Oyer PE; Jamieson SW; Bieber CP; Henle W; Shumway NE
    J Heart Transplant; 1985 May; 4(3):307-11. PubMed ID: 3039097
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incidence of cancer after immunosuppressive treatment for heart transplantation.
    Ippoliti G; Rinaldi M; Pellegrini C; Viganò M
    Crit Rev Oncol Hematol; 2005 Oct; 56(1):101-13. PubMed ID: 15979322
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Progress in cardiac transplantation.
    Mckenzie FN; Heimbecker RO
    Rinsho Kyobu Geka; 1982; 2(2):301-2. PubMed ID: 6760356
    [No Abstract]   [Full Text] [Related]  

  • 28. Prevalence of accelerated coronary artery disease in heart transplant survivors. Comparison of cyclosporine and azathioprine regimens.
    Gao SZ; Schroeder JS; Alderman EL; Hunt SA; Valantine HA; Wiederhold V; Stinson EB
    Circulation; 1989 Nov; 80(5 Pt 2):III100-5. PubMed ID: 2805287
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiac transplantation at the Texas Heart Institute: recent experience.
    Frazier OH; Cooley DA; Okereke OU; VanBuren CT; Kahan BD
    Tex Med; 1985 Dec; 81(12):48-52. PubMed ID: 3911472
    [No Abstract]   [Full Text] [Related]  

  • 30. Cyclosporine. Heart and lung transplantation.
    Transplant Proc; 1983 Dec; 15(4 Suppl 1-2):2546-81. PubMed ID: 6420962
    [No Abstract]   [Full Text] [Related]  

  • 31. The role of suppressor T lymphocytes in the induction of specific immunologic unresponsiveness to rat cardiac allografts by donor leukocytes and cyclosporine.
    Oluwole SF; Fawwaz RA; Reemtsma K; Hardy MA
    Transplant Proc; 1988 Jun; 20(3 Suppl 3):1038-44. PubMed ID: 2968694
    [No Abstract]   [Full Text] [Related]  

  • 32. Immunosuppression for cardiac transplantation--the past, present and future.
    O'Neill JO; Taylor DO; Starling RC
    Transplant Proc; 2004 Mar; 36(2 Suppl):309S-313S. PubMed ID: 15041359
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Personal experience with immunosuppression with cyclosporin A in kidney transplantation].
    Bosković S
    Acta Chir Iugosl; 1989; 36(1):67-81. PubMed ID: 2652959
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Are steroids essential for successful maintenance of immunosuppression in heart transplantation?
    Katz MR; Barnhart GR; Szentpetery S; Rider S; Thompson JA; Hess M; Hastillo A; Lower RR
    J Heart Transplant; 1987; 6(5):293-7. PubMed ID: 3316555
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Temporal effect of cyclosporine immunosuppression on T lymphocyte subsets, Ia-reactive cells, and donor-specific immunity in cardiac allograft recipients.
    Mazaheri R; Stiller CR; Keown P; McKenzie N; Howson W; Farrow K; McFarlane D; Sinclair NR
    Transplant Proc; 1984 Dec; 16(6):1537-9. PubMed ID: 6390861
    [No Abstract]   [Full Text] [Related]  

  • 36. Evaluation of the in vivo dose-response relationship of immunosuppressive drugs using a mouse heart transplant model: application to cyclosporine.
    Babany G; Morris RE; Babany I; Kates RE
    J Pharmacol Exp Ther; 1988 Jan; 244(1):259-62. PubMed ID: 3275773
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effectiveness of cyclosporin in experimental pancreas transplant].
    Prieto M; Sutherland DE; Fernández-Cruz L; Heil J; Najarian J
    Rev Quir Esp; 1988; 15(1):32-4. PubMed ID: 3153356
    [No Abstract]   [Full Text] [Related]  

  • 38. Cyclosporine coverage during the risk period leads to 100% long-term graft acceptance in the rat.
    Lim SM; White DJ; Calne RY
    Transplant Proc; 1988 Jun; 20(3 Suppl 3):1013-5. PubMed ID: 3291211
    [No Abstract]   [Full Text] [Related]  

  • 39. Orthotopic and heterotopic transplantation of the heart: the Cape Town experience.
    Cooper DK
    Ann R Coll Surg Engl; 1984 Jul; 66(4):228-34. PubMed ID: 6378042
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of low-dose cyclosporine A on toxicity and rejection in cardiac transplantation.
    Spratt P; Esmore D; Baron D; Shanahan MX; Farnsworth AE; Chang VP
    Transplant Proc; 1987 Apr; 19(2):2847-50. PubMed ID: 3551225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.